Remibrutinib (Rhapsido) for chronic spontaneous urticaria

Overview of attention for article published in Trends in Pharmacological Sciences, May 2026

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (64th percentile)
Good Attention Score compared to outputs of the same age and source (71st percentile)

So far, Altmetric has seen 4 X posts from 3 X users, with an upper bound of 18,728 followers.

RT @TrendsinPharma: Remibrutinib (Rhapsido) for chronic spontaneous urticaria https://t.co/DJB1aTuG6K https://t.co/fgZL84WF2B

Remibrutinib (Rhapsido) for chronic spontaneous urticaria https://t.co/DJB1aTuG6K https://t.co/fgZL84WF2B

Our latest on BTK inhibitors-Remibrutinib (Rhapsido) for chronic spontaneous urticaria: Trends in Pharmacological Sciences https://t.co/4abwyDcW8y

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity.